UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1655P Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study

Annals of oncology, 2024-09, Vol.35, p.S998-S998

2024

Volltextzugriff (PDF)

Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG)

ANNALS OF ONCOLOGY, 2018-10, Vol.29 Suppl 8, p.viii132

2018

Volltextzugriff (PDF)

1582P Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)

Annals of oncology, 2024-09, Vol.35, p.S955-S955

2024

Volltextzugriff (PDF)

49P Prognostic relevance of baseline exosome-delivered PD-1, PD-L1, pan-BTN3As and BTN3A1 in advanced cholangiocarcinoma patients: Can immune checkpoints act as a sentinel for predicting survival?

Annals of oncology, 2024-09, Vol.35, p.S231-S231

2024

Volltextzugriff (PDF)

208P Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge?

Annals of oncology, 2024-09, Vol.35, p.S300-S300

2024

Volltextzugriff (PDF)

1221P The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors

Annals of oncology, 2023-10, Vol.34, p.S716-S716

2023

Volltextzugriff (PDF)

Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer

Annals of oncology, 2018-10, Vol.29, p.viii531-viii531

2018

Volltextzugriff (PDF)

Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors

Annals of oncology, 2018-10, Vol.29, p.viii500-viii500

2018

Volltextzugriff (PDF)

Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non-small cell lung cancer

Annals of oncology, 2018-10, Vol.29, p.viii512-viii512

2018

Volltextzugriff (PDF)

A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients

Annals of oncology, 2018-10, Vol.29, p.viii96-viii96

2018

Volltextzugriff (PDF)

1094P The clinical potential of circulating-free DNA (cfDNA) for real-time longitudinally monitoring clinical outcomes in a real-world first-line non-small cell lung cancer (NSCLC) prospective study

Annals of oncology, 2022-09, Vol.33, p.S1051

2022

Volltextzugriff (PDF)

904MO Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD)

Annals of oncology, 2022-09, Vol.33, p.S961-S962

2022

Volltextzugriff (PDF)

EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy

Annals of oncology, 2019-04, Vol.30, p.ii59-ii59

2019

Volltextzugriff (PDF)

P-264 The molecular-metabolic interplay in metastatic gastrointestinal stromal tumors (GISTs): The predictive role of body mass index

Annals of oncology, 2022-06, Vol.33, p.S341

2022

Volltextzugriff (PDF)

Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy

Annals of oncology, 2019-04, Vol.30, p.ii56-ii56

2019

Volltextzugriff (PDF)

Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi30

2017

Volltextzugriff (PDF)

1974P Improved risk stratification with a prognostic nomogram incorporating the KIT-Variant Allele Frequency (VAF) and the 557/558 deletions: Results from a multi-institutional study in a cohort of intermediate-risk GIST patients

Annals of oncology, 2023-10, Vol.34, p.S1054-S1054

2023

Volltextzugriff (PDF)

53P Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase I TriComB study

Annals of oncology, 2024-06, Vol.35, p.S25-S26

2024

Volltextzugriff (PDF)

122P Can circulating PD-1, PD-L1, pan-BTN3As, BTN3A1, BTN2A1 and BTLA levels enhance prognostic power of serum CA125 in patients with advanced high-grade serous ovarian cancer?

Annals of oncology, 2022-09, Vol.33, p.S593-S594

2022

Volltextzugriff (PDF)

598P Can circulating PD-L1 levels, age at diagnosis and peritoneal carcinomatosis act as survival predictors in patients with advanced high-grade serous ovarian cancer?

Annals of oncology, 2022-09, Vol.33, p.S820

2022

Volltextzugriff (PDF)

Genetic counseling for BRCA1/BRCA2 testing

Annals of oncology, 2017-10, Vol.28, p.vi79-vi79

2017

Volltextzugriff (PDF)

Strategy of monitoring metastatic breast cancer (M-MBC) in clinical practice: more or less intensive?

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi30

2017

Volltextzugriff (PDF)

449MO Macrophage derived immunotherapy in glioblastoma: Phase I TEM-GBM-001 results

Annals of oncology, 2024-09, Vol.35, p.S409-S409

2024

Volltextzugriff (PDF)

1251P Retrospective evaluation of inflammatory biomarkers in patients affected by unresectable stage III NSCLC: Final results of NEUTRALITY trial

Annals of oncology, 2024-09, Vol.35, p.S800-S801

2024

Volltextzugriff (PDF)

1 – 25 von 157

Suche als RSS-Feed

Aktive Filter

ThemaExact Sciences And Technology

ThemaMale

ThemaOncology

Zeitschrift / SerieAnnals Of Oncology

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(157)

Publikationsform

Artikel
(157)

Sprache

Englisch
(157)

Erscheinungsjahr

n.n

Kollektion

Neu hinzugefügt

... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

1655P Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study

Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial

Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600-mutant high-grade glioma (HGG) or low-grade glioma (LGG)

1582P Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)

49P Prognostic relevance of baseline exosome-delivered PD-1, PD-L1, pan-BTN3As and BTN3A1 in advanced cholangiocarcinoma patients: Can immune checkpoints act as a sentinel for predicting survival?

208P Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge?

1221P The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors

Effects of antibiotic use during immunotherapy in metastatic non-small cell lung cancer

Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors

Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non-small cell lung cancer

A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients

1094P The clinical potential of circulating-free DNA (cfDNA) for real-time longitudinally monitoring clinical outcomes in a real-world first-line non-small cell lung cancer (NSCLC) prospective study

904MO Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD)

EPSILoN score: Validation cohort of a prognostic score in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy

P-264 The molecular-metabolic interplay in metastatic gastrointestinal stromal tumors (GISTs): The predictive role of body mass index

Characterization of patients with metastatic non-small cell lung cancer obtaining long term benefit from immunotherapy

Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey

1974P Improved risk stratification with a prognostic nomogram incorporating the KIT-Variant Allele Frequency (VAF) and the 557/558 deletions: Results from a multi-institutional study in a cohort of intermediate-risk GIST patients

53P Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase I TriComB study

122P Can circulating PD-1, PD-L1, pan-BTN3As, BTN3A1, BTN2A1 and BTLA levels enhance prognostic power of serum CA125 in patients with advanced high-grade serous ovarian cancer?

598P Can circulating PD-L1 levels, age at diagnosis and peritoneal carcinomatosis act as survival predictors in patients with advanced high-grade serous ovarian cancer?

Genetic counseling for BRCA1/BRCA2 testing

Strategy of monitoring metastatic breast cancer (M-MBC) in clinical practice: more or less intensive?

449MO Macrophage derived immunotherapy in glioblastoma: Phase I TEM-GBM-001 results

1251P Retrospective evaluation of inflammatory biomarkers in patients affected by unresectable stage III NSCLC: Final results of NEUTRALITY trial

Aktive Filter

Suchergebnisse filtern